{"id":"NCT02492165","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects","officialTitle":"Immunogenicity and Safety of a Single Primary Dose of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) Given to Healthy Subjects in Vietnam","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-06","primaryCompletion":"2016-03","completion":"2016-06","firstPosted":"2015-07-08","resultsPosted":"2016-11-29","lastUpdate":"2022-03-28"},"enrollment":250,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Japanese Encephalitis"],"interventions":[{"type":"BIOLOGICAL","name":"Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)","otherNames":["IMOJEV®"]},{"type":"BIOLOGICAL","name":"Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)","otherNames":["IMOJEV®"]},{"type":"BIOLOGICAL","name":"Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)","otherNames":["IMOJEV®"]},{"type":"BIOLOGICAL","name":"Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)","otherNames":["IMOJEV®"]}],"arms":[{"label":"Age 9 Months through 4 Years Group","type":"EXPERIMENTAL"},{"label":"Age 5 Years through 11 Years Group","type":"EXPERIMENTAL"},{"label":"Age 12 Years through 17 Years Group","type":"EXPERIMENTAL"},{"label":"Age 18 Years through 60 Years Group","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to describe the immunogenicity and safety of IMOJEV® in adult and pediatric populations in Vietnam and serve a bridging study to compare immunogenicity, reactogenicity, and safety data obtained with IMOJEV® in the Vietnamese population with data from other Asian pediatric populations.\n\nPrimary objective:\n\n\\- To describe the safety profile of a single dose of IMOJEV®.\n\nSecondary objectives:\n\n* To evaluate the immune response to JE 28 days after the administration of a single dose of IMOJEV® in healthy Vietnamese subjects aged from 9 months to 60 years.","primaryOutcome":{"measure":"Number of Participants With Solicited Injection Site Reactions and Systemic Events Following a Single Primary Dose of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®)","timeFrame":"Day 0 up to Day 14 post-vaccination","effectByArm":[{"arm":"9 Months to 4 Years","deltaMin":35,"sd":null},{"arm":"5 to 11 Years","deltaMin":8,"sd":null},{"arm":"12 to 17 Years","deltaMin":11,"sd":null},{"arm":"18 to 60 Years","deltaMin":8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"9 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":17},"locations":{"siteCount":1,"countries":["Vietnam"]},"refs":{"pmids":["29081368"],"seeAlso":["http://www.sanofipasteur.com"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":100},"commonTop":["Injection site Tenderness/Pain","Appetite loss","Headache","Malaise","Fever"]}}